GLP-1 drugs linked to lower fracture risk in adults with type 2 diabetes

A new study by UCLA Health reveals that GLP-1 medications may lower the risk of serious fractures in adults with type 2 diabetes. Type 2 diabetes and obesity increase the likelihood of fragile fractures, often caused by minor trauma like falling from a standing height. While GLP-1 receptor agonists can help users shed weight, concerns have arisen about whether rapid weight loss could weaken bones and increase fracture risk.

Using electronic health records from nearly 134,000 U.S. adults aged 50-90 with type 2 diabetes, researchers found that GLP-1 use was linked to a 21% lower risk of fragility fractures over three years compared to DPP-4 inhibitor use, with the most significant reductions seen in hip, femur, and spine fractures. The reduced risk was exclusive to those with type 2 diabetes compared to a similar group without diabetes.

Dr. Christopher Hamad explained that most previous studies were too small or inadequately designed to answer this question, but the large dataset allowed for a more comprehensive understanding of how GLP-1 medications might impact fracture risk and bone health. However, the findings come from a retrospective observational study, meaning they cannot prove causality, and further prospective and translational studies are required to confirm the findings and their long-term effects on bone health.